PL416764A1 - Sposób oczyszczania daptomycyny - Google Patents

Sposób oczyszczania daptomycyny

Info

Publication number
PL416764A1
PL416764A1 PL416764A PL41676401A PL416764A1 PL 416764 A1 PL416764 A1 PL 416764A1 PL 416764 A PL416764 A PL 416764A PL 41676401 A PL41676401 A PL 41676401A PL 416764 A1 PL416764 A1 PL 416764A1
Authority
PL
Poland
Prior art keywords
daptomycin
solution
monomeric
purification
separating
Prior art date
Application number
PL416764A
Other languages
English (en)
Other versions
PL236352B1 (pl
Inventor
Thomas J. Kelleher
Jan-Ji Lai
Joseph P. Decourcey
Paul D. Lynch
Maurizio Zenoni
Auro R. Tagliani
Original Assignee
Cubist Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26873002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL416764(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharmaceuticals, Inc. filed Critical Cubist Pharmaceuticals, Inc.
Publication of PL416764A1 publication Critical patent/PL416764A1/pl
Publication of PL236352B1 publication Critical patent/PL236352B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Wynalazek dotyczy sposobu oczyszczania daptomycyny obejmującego etapy: a) poddawania daptomycyny warunkom, w których przez zmianę pH wytwarzany jest roztwór micelarnej daptomycyny; b) oddzielania miceli daptomycyny z roztworu micelarnej daptomycyny od zanieczyszczeń o niskiej masie cząsteczkowej z zastosowaniem techniki rozdziału względem wielkości; c) poddawania daptomycyny warunkom, w których przez zmianę pH wytwarzany jest roztwór monomerycznej daptomycyny; oraz d) oddzielania cząsteczek monomerycznej daptomycyny z roztworu monomerycznej daptomycyny od zanieczyszczeń o wysokiej masie cząsteczkowej lub agregatów z zastosowaniem techniki rozdziału względem wielkości.
PL416764A 2000-01-20 2001-01-18 Sposób oczyszczania daptomycyny PL236352B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17717000P 2000-01-20 2000-01-20
US09/735,191 US6696412B1 (en) 2000-01-20 2000-11-28 High purity lipopeptides, Lipopeptide micelles and processes for preparing same
PCT/US2001/001748 WO2001053330A2 (en) 2000-01-20 2001-01-18 High purity lipopeptides, lipopeptide micelles, processes for preparing same and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
PL416764A1 true PL416764A1 (pl) 2016-05-23
PL236352B1 PL236352B1 (pl) 2021-01-11

Family

ID=26873002

Family Applications (3)

Application Number Title Priority Date Filing Date
PL356898A PL214000B1 (pl) 2000-01-20 2001-01-18 Sposób oczyszczania daptomycyny
PL400575A PL226956B1 (pl) 2000-01-20 2001-01-18 Sposób oczyszczania daptomycyny
PL416764A PL236352B1 (pl) 2000-01-20 2001-01-18 Sposób oczyszczania daptomycyny

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL356898A PL214000B1 (pl) 2000-01-20 2001-01-18 Sposób oczyszczania daptomycyny
PL400575A PL226956B1 (pl) 2000-01-20 2001-01-18 Sposób oczyszczania daptomycyny

Country Status (25)

Country Link
US (7) US6696412B1 (pl)
EP (6) EP2940036B1 (pl)
JP (2) JP5303087B2 (pl)
KR (4) KR101174140B1 (pl)
CN (5) CN1404487A (pl)
AT (2) ATE449785T1 (pl)
AU (1) AU784937B2 (pl)
BR (1) BRPI0107731B8 (pl)
CA (2) CA2743326C (pl)
CY (2) CY1109846T1 (pl)
CZ (2) CZ307877B6 (pl)
DE (2) DE60115383T2 (pl)
DK (2) DK1586580T3 (pl)
ES (4) ES2336336T3 (pl)
HK (1) HK1054240A1 (pl)
HU (1) HUP0203969A2 (pl)
IL (3) IL150733A0 (pl)
IS (1) IS6470A (pl)
MX (1) MXPA02007132A (pl)
NO (1) NO20023476L (pl)
NZ (1) NZ520324A (pl)
PL (3) PL214000B1 (pl)
PT (2) PT2264047E (pl)
RU (1) RU2311460C9 (pl)
WO (1) WO2001053330A2 (pl)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696412B1 (en) * 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
CA2301336A1 (en) * 2000-03-17 2001-09-17 Michael T. Kelly Topical treatment of rosacea
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
JP2004525108A (ja) 2000-12-18 2004-08-19 キュービスト ファーマスーティカルズ インコーポレイテッド 精製リポペプチドの調製方法
WO2003017924A2 (en) 2001-08-06 2003-03-06 Cubist Pharmaceuticals, Inc. Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
EP1932853A1 (en) 2001-08-06 2008-06-18 Cubist Pharmaceutical Inc. Novel depsipeptides and process for preparing same
NZ570989A (en) * 2002-05-16 2010-01-29 Sepracor Inc Amines that inhibit a mammalian anandamide transporter, and methods of use thereof
AU2003240545A1 (en) 2002-06-06 2003-12-22 Therapeutics Corporation Genome Use of ramoplanin to treat diseases associated with the use of antibiotics
ATE448775T1 (de) * 2002-08-29 2009-12-15 Activbiotics Pharma Llc Rifalazil zur behandlung von infektionen mit clostridium difficile
US7145762B2 (en) * 2003-02-11 2006-12-05 Taser International, Inc. Systems and methods for immobilizing using plural energy stores
KR100554481B1 (ko) * 2004-06-30 2006-03-03 씨제이 주식회사 반코마이신 염산염의 정제방법
EP1860943A4 (en) * 2005-03-10 2008-06-18 Smithkline Beecham Corp NOVEL PROCEDURE
EP1798237A1 (en) * 2005-12-16 2007-06-20 Pharmatex Italia Srl Process for the purification of macrolide antibiotics
EP2018864A1 (en) * 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
RU2356535C2 (ru) * 2007-07-23 2009-05-27 Закрытое Акционерное Общество "Биокад" Суппозитории комбинированного действия для лечения инфекционных гинекологических заболеваний (варианты)
CN101868472B (zh) 2007-11-21 2013-05-29 尔察祯有限公司 抗菌性氨基糖苷类似物
CA2725043A1 (en) * 2008-05-21 2009-11-26 Daedalus Innovations Llc Solubilization of proteins in reverse micelles by extraction from a solid support
WO2009144739A1 (en) * 2008-05-26 2009-12-03 Biocon Limited Amorphous daptomycin and a method of purification thereof
DE102008046610A1 (de) * 2008-09-09 2010-03-11 Biomet Deutschland Gmbh Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt
ES2543457T5 (es) * 2009-02-19 2021-12-22 Xellia Pharmaceuticals Aps Procedimiento para purificar lipopéptidos
CN101830970B (zh) * 2009-03-12 2012-06-27 成都雅途生物技术有限公司 一种高纯度达托霉素(Daptomycin)的纯化制备方法
CN101899094B (zh) * 2009-06-01 2012-11-21 安徽丰原发酵技术工程研究有限公司 一种高纯达托霉素的制备方法
WO2011002258A2 (ko) * 2009-07-02 2011-01-06 한양대학교 산학협력단 아르기닌 기제 양친성 펩티드 마이셀
US8431539B2 (en) * 2009-09-17 2013-04-30 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
US20110124551A1 (en) * 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
CA2781666C (en) * 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
CN101777094B (zh) * 2010-02-01 2011-11-16 天津大学 达托霉素生产菌玫瑰孢链霉菌的代谢网络分析方法
KR101151878B1 (ko) * 2010-06-08 2012-05-31 미원상사주식회사 지방산 트리펩타이드염 및 이를 함유하는 항균 조성물
CN102276696B (zh) * 2010-06-09 2014-11-05 上海来益生物药物研究开发中心有限责任公司 达托霉素的纯化方法
RU2448725C2 (ru) * 2010-07-13 2012-04-27 Российская Федерация, От Имени Которой Выступает Министерство Образования И Науки Российской Федерации Способ повышения бактерицидной активности
CN101957348B (zh) * 2010-09-17 2012-07-25 中华人民共和国珠海出入境检验检疫局 同时检测食品中氟喹诺酮类药物和氯霉素类药物的方法
KR200457763Y1 (ko) * 2010-09-30 2012-01-02 상 택 임 형광등 낙하 방지 기능을 갖는 안전소켓
JP5913367B2 (ja) 2011-01-05 2016-04-27 ホスピーラ インコーポレイテッド バンコマイシンの噴霧乾燥
CN102206694B (zh) * 2011-04-06 2013-10-16 山东新时代药业有限公司 一种含有癸酸的缓释组合物
WO2013012101A1 (ko) * 2011-07-15 2013-01-24 미원상사주식회사 지방산 트리펩타이드염 및 이를 함유하는 항균 조성물
CN103159829B (zh) * 2011-12-08 2014-11-05 北大方正集团有限公司 达托霉素的提取方法
CN102492024A (zh) * 2011-12-09 2012-06-13 厦门大学 从发酵液中提取达托霉素的方法
CN102675426B (zh) * 2012-04-26 2013-12-11 杭州华东医药集团生物工程研究所有限公司 一种达托霉素的提取纯化方法
WO2013173676A1 (en) * 2012-05-18 2013-11-21 Tufts Medical Center, Inc Polypeptide and lipophilic moiety conjugate compositions, formulations, and uses related thereto
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
PL4066849T3 (pl) 2012-09-11 2025-06-16 Hospira Australia Pty Ltd Preparaty daptomycyny i ich zastosowania
CN103724400B (zh) * 2012-10-10 2015-12-16 北大方正集团有限公司 一种分离纯化脱水达托霉素的方法
CN103848894A (zh) * 2012-11-30 2014-06-11 杨子剑 含有达托霉素结构的新化合物以及制备方法和用途
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
CN103224547B (zh) * 2013-04-28 2015-05-20 华北制药集团新药研究开发有限责任公司 一种达托霉素的分离纯化方法
CN104511011A (zh) * 2013-09-29 2015-04-15 山东新时代药业有限公司 一种达托霉素无菌粉末及其制备方法
CN104650189A (zh) * 2013-11-19 2015-05-27 北大方正集团有限公司 一种异构达托霉素的制备方法
KR101601089B1 (ko) * 2014-04-22 2016-03-09 주식회사 종근당바이오 신규한 답토마이신 생산 균주 및 이를 이용한 답토마이신의 제조방법
MX385925B (es) 2014-07-17 2025-03-18 The Medicines Co Oritavancina de alta pureza y método para producir la misma.
CN104387444B (zh) * 2014-11-13 2017-12-08 北大医药重庆大新药业股份有限公司 一种达托霉素杂质rs‑2高纯度样品的制备方法
KR101716879B1 (ko) * 2014-11-19 2017-03-17 주식회사 종근당바이오 데카노일 글리세라이드를 이용한 답토마이신의 생산방법
AR100034A1 (es) 2015-01-30 2016-09-07 Consejo Nac De Investig Científicas Y Técnicas (Conicet) Una composición farmacéutica soluble en agua que comprende, al menos, una sustancia terapéuticamente activa y, al menos, una sustancia con capacidad para formar micelas
CN105001305A (zh) * 2015-04-29 2015-10-28 利穗科技(苏州)有限公司 利用层析技术提取高纯度达托霉素的方法
CN106866789A (zh) * 2015-12-11 2017-06-20 北大方正集团有限公司 一种分离纯化达托霉素rs-8杂质的方法
CN106866791A (zh) * 2015-12-11 2017-06-20 北大方正集团有限公司 一种高纯度达托霉素内酯水解物的制备方法
CN106866790A (zh) * 2015-12-11 2017-06-20 北大方正集团有限公司 达托霉素RS-5/6、RS-7和RS-7a/7b杂质的制备方法
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
IT201600127655A1 (it) * 2016-12-16 2018-06-16 Gnosis Spa Processo per la purificazione di antibiotici lipopolipeptidici
AU2018338194B2 (en) 2017-09-22 2021-07-08 Becton, Dickinson And Company 4% trisodium citrate solution for use as a catheter lock solution
CN109589306A (zh) * 2017-09-30 2019-04-09 上海交通大学医学院附属第九人民医院 脂质体在制备用于清除蛋白结合毒素的药物制剂中的用途
CN107817307B (zh) * 2017-11-01 2020-12-25 重庆华邦制药有限公司 Hplc法分离测定帕司烟肼及其相关杂质的方法
CN109828037B (zh) * 2017-11-23 2021-11-23 中国科学院大连化学物理研究所 一种高通量富集和鉴定内源性n/o-连接糖肽的方法
US11964040B2 (en) 2017-12-28 2024-04-23 Locus Solutions Ipco, Llc Oral health composition comprising purified biosurfactants and/or their derivatives
PL237299B1 (pl) * 2018-02-09 2021-04-06 Boruta Zachem Biochemia Spolka Z Ograniczona Odpowiedzialnoscia Sposób oczyszczania i/lub rozdzielania surfaktyny z wykorzystaniem Chromatografii Przeciwprądowej
CN108333272A (zh) * 2018-03-02 2018-07-27 重庆华邦胜凯制药有限公司 Lc-msms法分离测定对氨基水杨酸及其相关杂质的方法
CN110339342A (zh) * 2018-04-03 2019-10-18 江苏恒瑞医药股份有限公司 一种达托霉素的盐或含盐的组合物及其制备方法
CN110577581A (zh) * 2018-06-07 2019-12-17 美国蓝博药业公司 一种新型的抑菌脂肽化合物、制备方法及其应用
US11643438B2 (en) 2018-07-20 2023-05-09 The Board Of Regents Of The University Of Oklahoma Antimicrobial peptides and methods of use
WO2020128506A1 (en) * 2018-12-21 2020-06-25 Arecor Limited Novel composition
CN111366644B (zh) * 2018-12-25 2022-07-26 江苏先声药业有限公司 一种比阿培南侧链有关物质的hplc检测方法
CN109444294B (zh) * 2018-12-27 2021-06-22 苏州莱奥生物技术有限公司 一种分离利奈唑胺和其手性异构体的高效液相色谱方法
CN109917047A (zh) * 2019-04-15 2019-06-21 陕西科技大学 超高效液相色谱-四极杆飞行时间质谱法同时筛查鱼中多类别药物残留的方法
CN110146620B (zh) * 2019-06-11 2022-04-19 福建医科大学孟超肝胆医院(福州市传染病医院) 一种uplc-ms/ms法同时检测血浆中五种抗结核药物的方法
CN113004373B (zh) * 2019-12-19 2024-08-13 鲁南制药集团股份有限公司 一种达托霉素的纯化方法
EP4117625A1 (en) 2020-03-12 2023-01-18 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
CN113929747A (zh) * 2020-06-29 2022-01-14 鲁南制药集团股份有限公司 一种制备达托霉素杂质RS-7a的方法
CN113929743A (zh) * 2020-06-29 2022-01-14 鲁南制药集团股份有限公司 一种制备达托霉素杂质rs-1和杂质rs-3的方法
CN111892647B (zh) * 2020-08-18 2022-04-29 丽珠集团福州福兴医药有限公司 一种提高达托霉素发酵产量的补料方法
CN112089823B (zh) * 2020-09-25 2024-02-06 珠海中科先进技术研究院有限公司 一种短梗霉素a和制霉菌素组合物及其复合软膏、凝胶剂以及喷剂
CN112684043A (zh) * 2020-12-16 2021-04-20 南京健友生化制药股份有限公司 一种达托霉素有关物质的检测方法
EP4248951A4 (en) * 2020-12-22 2024-10-23 Chugai Seiyaku Kabushiki Kaisha METHOD FOR THE MANUFACTURE OF MEDICAMENTS WITH A MIXED SOLVENT FREEZE-DRYING STEP
CN112898383A (zh) * 2021-01-29 2021-06-04 深圳海创生物科技有限公司 一种寡肽、活性肽组合物及其在制备具有抗炎作用的产品中的应用
CN113866330B (zh) * 2021-10-26 2023-08-22 丽珠集团福州福兴医药有限公司 一种脱水达托霉素的分离纯化方法和应用
WO2026111848A1 (en) 2024-11-21 2026-05-28 MAIA Pharmaceuticals, Inc. Daptomycin compositions

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE21978E (en) 1941-12-16 Vacuum cleaner
US21978A (en) 1858-11-02 Trap for animals
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
USRE32333E (en) 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
US4331594A (en) * 1978-10-16 1982-05-25 Eli Lilly And Company A-21978 Antibiotics and process for their production
EP0014815A3 (de) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
IE55221B1 (en) 1982-02-27 1990-07-04 Beecham Group Plc Antibacterial 1-normon-2-yl-heterocyclic compounds
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
IL68700A0 (en) 1982-05-21 1983-09-30 Lilly Co Eli Improvements relating to a-21978c cyclic peptide derivatives and their production
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CN1051200A (zh) * 1984-10-09 1991-05-08 伊莱利利公司 制备抗菌素a-21978c复合物或因子的方法
US4885243A (en) 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
US4800157A (en) 1985-09-09 1989-01-24 Eli Lilly And Company Process for producing the A-21978C antibiotics
US4865729A (en) 1985-11-04 1989-09-12 Sepragen Corporation Radial thin layer chromatography
US4840730A (en) 1986-07-25 1989-06-20 Sepragen Corporation Chromatography system using horizontal flow columns
US4708782A (en) 1986-09-15 1987-11-24 Sepragen Corporation Chromatography column-electrophoresis system
CA1319886C (en) 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
EP0294990A3 (en) 1987-06-10 1990-05-09 Eli Lilly And Company Chromatographic purification process
US4874843A (en) 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
US5271935A (en) 1988-02-05 1993-12-21 Hoechst Aktiengesellschaft Antibiotic, cammunocin, a process for the preparation thereof, and the use thereof as a pharmaceutical
CA1337758C (en) 1988-04-11 1995-12-19 Eli Lilly And Company Peptide antibiotics
CA2011365A1 (en) * 1989-03-06 1990-09-06 Eugene L. Inman Diluent formulation for daptomycin
US5202309A (en) 1989-06-30 1993-04-13 Merck & Co., Inc. Antibiotic cyclopeptide fermentation product
DE69031730T2 (de) 1990-01-26 1998-04-23 Hoechst Ag Neues Antibiotikum, Deoxymulündocandin, Verfahren zu seiner Produktion und Verwendung als Medikament
IL98349A (en) 1990-06-07 1995-05-26 Lilly Co Eli Diphylase lipopeptide
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
JPH04224197A (ja) 1990-12-26 1992-08-13 Fujitsu Ltd 生体高分子結晶化方法および装置
US5336756A (en) 1991-05-01 1994-08-09 Merck & Co., Inc. Process for crystalline cyclic lipopeptides
TW213468B (pl) 1991-06-29 1993-09-21 Hoechst Ag
EP0640095B1 (en) 1992-04-20 1998-07-01 Abbott Laboratories Process for making vancomycin
TW455591B (en) 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
WO1995005384A1 (en) 1993-08-13 1995-02-23 Smithkline Beecham Plc Derivatives of monic acids a and c having antibacterial, antimycoplasmatical, antifungal and herbicidal activity
US5756680A (en) 1994-01-05 1998-05-26 Sepragen Corporation Sequential separation of whey proteins and formulations thereof
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
IT1275427B (it) * 1995-05-16 1997-08-07 Bracco Spa Processo per la depirogenazione di soluzioni farmaceutiche iniettabili
US5955509A (en) 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
FR2755857B1 (fr) 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
FR2771640B1 (fr) 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
AU5528198A (en) 1997-12-03 1999-06-16 Immune Response Corporation, The Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
FR2772272B1 (fr) 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
FR2774687B1 (fr) * 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
EP2311436A1 (en) 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Stabilized protein crystals, formulations containing them and methods of making them
EP1100947A4 (en) 1998-08-07 2001-09-05 Merck & Co Inc METHOD FOR PRODUCING AN ANTIBIOTIC ACTIVE SUBSTANCE
HU230656B1 (hu) * 1998-09-25 2017-06-28 Cubist Pharmaceuticals Llc Daptomicin alkalmazása
CN1423656A (zh) 1999-12-15 2003-06-11 卡比斯特制药公司 作为抗菌剂的脂肽
BR0017026A (pt) 1999-12-15 2003-01-07 Cubist Pharm Inc Lipeptìdeos como agentes antibacterianos
IL150224A0 (en) 1999-12-15 2002-12-01 Cubist Pharm Inc Lipopeptides and pharmaceutical compositions containing the same
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
WO2002059145A1 (en) 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
JP2004525108A (ja) 2000-12-18 2004-08-19 キュービスト ファーマスーティカルズ インコーポレイテッド 精製リポペプチドの調製方法
US20050027113A1 (en) 2001-08-06 2005-02-03 Miao Vivian Pak Woon Compositions and methods relating to the daptomycin biosynthetic gene cluster
US20030144362A1 (en) 2002-01-28 2003-07-31 Utterberg David S. High viscosity antibacterials for cannulae
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
WO2004104019A2 (en) 2003-05-14 2004-12-02 Zengen, Inc. Anti-inflammatory/anti-microbial peptides for use in dialysis
JP2008546429A (ja) 2005-05-31 2008-12-25 キュービスト ファーマシューティカルズ， インコーポレイテッド バイオフィルム処理およびカテーテル救出のためのダプトマイシン
US9393093B2 (en) 2008-02-18 2016-07-19 Covidien Lp Clip for implant deployment device
US8431539B2 (en) 2009-09-17 2013-04-30 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
CA2781666C (en) 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
US9406568B2 (en) 2014-11-21 2016-08-02 International Business Machines Corporation Semiconductor structure containing low-resistance source and drain contacts
KR20220135825A (ko) 2021-03-31 2022-10-07 에스케이하이닉스 주식회사 반도체 장치 제조 방법

Also Published As

Publication number Publication date
KR20070044079A (ko) 2007-04-26
HK1217205A1 (en) 2016-12-30
EP1586580A3 (en) 2005-11-09
KR101174140B1 (ko) 2012-08-14
NZ520324A (en) 2004-06-25
PL400575A1 (pl) 2013-01-07
HUP0203969A2 (hu) 2003-03-28
WO2001053330A2 (en) 2001-07-26
HK1085746A1 (en) 2006-09-01
CN101240013A (zh) 2008-08-13
RU2311460C2 (ru) 2007-11-27
US20110207658A1 (en) 2011-08-25
HK1217204A1 (en) 2016-12-30
CZ307877B6 (cs) 2019-07-17
ES2336336T3 (es) 2010-04-12
PL214000B1 (pl) 2013-06-28
IL226636A0 (en) 2013-06-27
CA2398726A1 (en) 2001-07-26
ES2799706T3 (es) 2020-12-21
EP1586580A2 (en) 2005-10-19
US8604164B2 (en) 2013-12-10
EP2159229A1 (en) 2010-03-03
RU2311460C9 (ru) 2009-06-10
EP2264047A1 (en) 2010-12-22
PT2264047E (pt) 2015-09-22
JP5631439B2 (ja) 2014-11-26
WO2001053330A9 (en) 2002-10-17
US20140371135A1 (en) 2014-12-18
ATE449785T1 (de) 2009-12-15
DK2264047T3 (en) 2015-07-13
DE60140631D1 (de) 2010-01-07
EP2940034A1 (en) 2015-11-04
US8058238B2 (en) 2011-11-15
US20050009747A1 (en) 2005-01-13
JP5303087B2 (ja) 2013-10-02
WO2001053330A3 (en) 2002-04-18
PL226956B1 (pl) 2017-10-31
CA2398726C (en) 2012-01-10
CZ20022830A3 (cs) 2002-11-13
IL150733A0 (en) 2003-02-12
CN107082798A (zh) 2017-08-22
CY1116827T1 (el) 2018-03-07
PL236352B1 (pl) 2021-01-11
US20070191280A1 (en) 2007-08-16
NO20023476L (no) 2002-09-20
JP2013173785A (ja) 2013-09-05
ES2799702T3 (es) 2020-12-21
US9358267B2 (en) 2016-06-07
US20130280760A1 (en) 2013-10-24
CN102229650B (zh) 2014-03-12
KR20020083151A (ko) 2002-11-01
DK1586580T3 (da) 2010-03-29
KR101291494B1 (ko) 2013-10-17
US8129342B2 (en) 2012-03-06
ATE311405T1 (de) 2005-12-15
EP1252179B1 (en) 2005-11-30
AU3097801A (en) 2001-07-31
CZ305004B6 (cs) 2015-03-25
CN107082798B (zh) 2021-10-15
CA2743326C (en) 2015-04-07
CN102671181A (zh) 2012-09-19
PT1586580E (pt) 2010-02-17
PL356898A1 (pl) 2004-07-12
NO20023476D0 (no) 2002-07-19
JP2003520807A (ja) 2003-07-08
CN102229650A (zh) 2011-11-02
CN101240013B (zh) 2012-05-23
HK1151546A1 (en) 2012-02-03
RU2002122114A (ru) 2004-02-27
EP1586580B1 (en) 2009-11-25
US20120149062A1 (en) 2012-06-14
KR20110126737A (ko) 2011-11-23
HK1120528A1 (en) 2009-04-03
HK1054240A1 (zh) 2003-11-21
DE60115383D1 (de) 2006-01-05
US6696412B1 (en) 2004-02-24
EP2940034B1 (en) 2020-05-06
EP2940036B1 (en) 2020-05-06
IL219889A (en) 2017-01-31
BRPI0107731B1 (pt) 2015-08-11
IS6470A (is) 2002-07-12
DE60115383T2 (de) 2006-08-17
CN1404487A (zh) 2003-03-19
KR20120065440A (ko) 2012-06-20
CA2743326A1 (en) 2001-07-26
MXPA02007132A (es) 2004-10-14
US8853357B2 (en) 2014-10-07
IL226636A (en) 2017-03-30
EP2264047B1 (en) 2015-06-24
AU784937B2 (en) 2006-08-03
CY1109846T1 (el) 2014-09-10
BR0107731A (pt) 2002-10-01
IL219889A0 (en) 2012-06-28
EP2940036A1 (en) 2015-11-04
BRPI0107731B8 (pt) 2021-05-25
ES2547281T3 (es) 2015-10-02
EP1252179A2 (en) 2002-10-30

Similar Documents

Publication Publication Date Title
BRPI0308385A8 (pt) processo para purificar uma composição compreendendo ácido (met)acrílico, aparelho para produzir ácido (met)acrílico e aparelho para polimerizar ácido (met)acrílico
EP2039699A3 (en) Extractive methods for purifying sucralose
EP1574527A4 (en) REINFORCEMENT PROCESS FOR AQUEOUS FLUORO POLYMER EMULSIONS, PURIFIED EMULSIONS AND FLUOROUS FINISHES
PL1797105T3 (pl) Zawierające fosfor pochodne heptazyny, sposób ich wytwarzania i ich zastosowanie jako środków ogniochronnych
DE60140631D1 (de) Verfahren zur aufreinigung von daptomycin
DK1809663T3 (da) Fremgangsmåde til oprensning af FSH
ATE532881T1 (de) Verfahren zur gewinnung von zuckern
ATE430160T1 (de) Lipopeptid-stereoisomere, verfahren zu ihrer herstellung und nützliche zwischenprodukte
ATE328490T1 (de) Leinsaat-proteinisolat und verfahren zur herstellung
ATE308495T1 (de) Verfahren zur herstellung von octafluorocyclobutan
DK1789445T3 (da) Fremgangsmåde til fjernelse af fibronektin fra plasmafraktioner
ATE358666T1 (de) Verfahren zur reinigung von dimethylacetamid (dmac)
DE602005006254D1 (de) Verfahren zur reinigung eines schmelzflüssigen metalls
DE60000796D1 (de) Reinigung von Lipstatin
IT1319234B1 (it) Processo di preparazione di gabapentina.
ATE306564T1 (de) Verfahren zur aufreinigung von maltose
ATE452123T1 (de) Verfahren zur gewinnung von reinem n- vinylpyrrolidon
NL1019899A1 (nl) Verwijdering van onzuiverheden uit koolwaterstofstromen.
WO2002004544A3 (en) Polymers and polymerization processes
DE50115655D1 (de) Verfahren zur herstellung von unsymmetrischen 4,6-bis(aryloxy)pyrimidin-derivaten
BRPI0408417A (pt) métodos para a produção de um resìduo de gla purificado contendo serina protease, para a purificação de um resìduo de gla contendo serina protease e para estabilização de um resìduo de gla contendo serina protease, e, composição
DE50107344D1 (de) Herstellung von polygalakturoniden und ihre verwendung als lebensmittelzusatzstoffe
ATE365153T1 (de) Verfahren zur abtrennung von triethanolamin aus einem durch die umsetzung von ammoniak mit ethylenoxid erhaltenen stoffgemisch
NO20015874L (no) Fremgangsmåte for fremstilling av alginat som har et höyt mannuronsyre-innhold
ATE267827T1 (de) Verfahren zur herstellung von hoch reinem pemirolast